Myditin (Pridinol Mesilate)

Pridinol mesilate acts centrally by blocking acetylcholine receptors in the spinal cord and brainstem, which dampens reflex pathways that maintain muscle tone. This anticholinergic action reduces the excitability of muscle spindles, leading to relaxation of skeletal muscles without directly affecting the muscle fibers.

The appropriate dose of Myditin is determined by the prescribing healthcare professional based on the individual’s condition, age, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for pridinol mesilate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should discuss the risks and benefits with the patient before prescribing.

To place an order, submit an enquiry on the Myditin product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Myditin (pridinol mesilate) is a centrally acting muscle relaxant with anticholinergic properties, distinguishing it from purely sedative agents like cyclobenzaprine. It offers muscle tone reduction with a different side‑effect profile, often resulting in less profound sedation but a higher likelihood of anticholinergic effects such as dry mouth.

Myditin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Myditin is taken orally as directed by a healthcare professional. The tablet or oral formulation should be swallowed whole with water, unless the prescriber advises otherwise. It is typically taken with or without food, depending on individual tolerance.

Serious risks include severe allergic reactions such as rash, swelling, or breathing difficulties, as well as rare but serious skin conditions like Stevens‑Johnson syndrome. Hepatic dysfunction and cardiac arrhythmias have also been reported, especially in patients with pre‑existing liver or heart disease.

Myditin is contraindicated in patients with known hypersensitivity to pridinol mesilate or any excipients in the formulation. Caution is advised for individuals with severe anticholinergic sensitivity, uncontrolled glaucoma, or significant hepatic impairment. Pregnant or breastfeeding women should only use it if clearly indicated by a physician.